window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-64619718-7');
Loading...
Partnering2021-03-03T11:07:55+00:00

Overview

We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical and biotechnology companies, and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Recently disclosed research collaborations include those with Servier, Daiichi Sankyo, Lundbeck, PhoreMost, Taisho and Asahi Kasei Pharma, and we seek additional partnerships.

To find out more about partnering with us, please contact us.

Research collaborations

We are involved in a number of research collaborations with major pharmaceutical and biotechnology companies, and academic partners. These range from early stage research, establishing target tractability, through to late-stage lead optimisation programs. We value close cooperation with our collaborators to ensure that the combined strengths of the partners are most effectively deployed to deliver drug candidates. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success.

Recently disclosed collaborations include those with:

Servier: two development stage collaborations on the Bcl-2 family of proteins and four further research collaborations on undisclosed oncology targets.

Daiichi Sankyo: a research collaboration on undisclosed oncology targets.

Lundbeck: a research collaboration targeting LRRK2 for the treatment of Parkinson’s disease.

Asahi Kasei Pharma: a research collaboration targeting IRAK4.

PhoreMost:  a research collaboration on an undisclosed novel oncology target.

Taisho: a research collaboration on the antibacterial target, LpxC.

For further information about collaboration opportunities, or to get more information about Vernalis Research capabilities, please feel free to contact us.

Vernalis Partnering Douglas Williamson Lee Walmsley Ijen Chen Claire Walmsley

Pre-clinical candidates

Drug discovery activities at Vernalis and with collaborators have generated pre-clinical candidates for many targets in various therapeutic areas.

Therapeutic area

CandidateTherapeutic areaTarget
V158866CNSFAAH Neuritek Therapeutics
CPI-444Immuno-oncologyA2A Corvus Pharmaceuticals
VipadenantImmuno-oncologyA2A Redox Therapies (a BMS company)
AK179InflammationIRAK4 Asahi Kasei Pharma
S55746OncologyBcl-2 Servier in collaboration with Novartis
S65487OncologyBcl-2 Servier in collaboration with Novartis
S64315OncologyMcl-1 Servier in collaboration with Novartis
V158411OncologyChk1 Vernalis
VER250840OncologyChk1 Ligand Pharmaceuticals
LuminespibOncologyHSP90 Ligand Pharmaceuticals